MCID: ANG020
MIFTS: 59

Angiosarcoma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angiosarcoma

MalaCards integrated aliases for Angiosarcoma:

Name: Angiosarcoma 12 77 60 38 56 6 15 41 17
Hemangiosarcoma 12 45 74

Characteristics:

Orphanet epidemiological data:

60
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0001816
KEGG 38 H01666
MeSH 45 D006394
NCIt 51 C3088 C9275
SNOMED-CT 69 33176006 39000009
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0018923
Orphanet 60 ORPHA263413

Summaries for Angiosarcoma

Disease Ontology : 12 A vascular cancer that derives from the cells that line the walls of blood vessels or lymphatic vessels.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to liver angiosarcoma and lymphangiosarcoma. An important gene associated with Angiosarcoma is PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ethiodized oil and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and bone, and related phenotypes are Decreased cell migration and Increased senescence-associated beta-galactosidase protein expression after pRB stimulation

Wikipedia : 77 Angiosarcoma is a cancer of the cells that line the walls of blood vessels or lymphatic vessels. The... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 442)
# Related Disease Score Top Affiliating Genes
1 liver angiosarcoma 34.3 KRAS VIM VWF
2 lymphangiosarcoma 32.7 FLT4 MYC PROX1 VEGFA VWF
3 epithelioid hemangioendothelioma 32.6 FLT1 KDR VEGFA
4 intravascular papillary endothelial hyperplasia 32.6 VEGFA VIM
5 hemangioendothelioma 32.0 FLI1 FLT4 KDR PECAM1
6 kaposi sarcoma 30.6 KDR MYC VEGFA
7 sarcoma 30.2 FLI1 KDR KIT KRAS VIM
8 pyogenic granuloma 30.0 TEK VEGFA
9 malignant peripheral nerve sheath tumor 29.9 KIT MUC1 VIM
10 malignant epithelioid hemangioendothelioma 29.9 FLT4 KDR MYC
11 adenoid squamous cell carcinoma 29.9 KRT8 VIM
12 benign breast phyllodes tumor 29.8 KIT VIM
13 adenocarcinoma 29.8 KDR KIT KRAS MUC1 MYC VEGFA
14 secretory meningioma 29.7 MUC1 VIM
15 gastrointestinal stromal tumor 29.7 KIT KRAS VEGFA VIM
16 thyroid cancer 29.7 KDR KIT KRAS MYC VEGFA
17 carcinosarcoma 29.6 KIT KRAS MUC1 VIM
18 arteries, anomalies of 29.6 FLT1 VEGFA VWF
19 cavernous hemangioma 29.6 KDR KIT MUC1 PECAM1 VIM
20 lymphangioma 29.5 FLT4 KDR PROX1 VEGFA VIM
21 hemangioma 29.5 FLT1 FLT4 KDR KRAS PECAM1 PROX1
22 perivascular epithelioid cell tumor 29.5 KIT MUC1 VIM
23 capillary hemangioma 29.1 FLT1 KDR PECAM1 TEK VEGFA
24 epithelioid sarcoma 29.1 KRT8 MUC1 VIM
25 lung cancer 29.0 FLT1 FLT4 KDR KIT KRAS MYC
26 merkel cell carcinoma 29.0 KIT KRT8 MUC1
27 sarcoma, synovial 28.8 KIT KRT8 MUC1 VIM
28 ewing sarcoma 28.5 FLI1 FLT1 KDR KIT MYC VEGFA
29 breast cancer 28.4 FLT1 FLT4 KDR KIT KRAS KRT8
30 renal cell carcinoma, nonpapillary 28.3 FLT1 FLT4 KDR KIT KRT8 MUC1
31 gastric adenocarcinoma 28.2 KDR KIT KRAS KRT8 MUC1 MYC
32 breast angiosarcoma 12.5
33 spleen angiosarcoma 12.4
34 skin angiosarcoma 12.4
35 thyroid angiosarcoma 12.4
36 angiosarcoma of the scalp 12.4
37 pediatric angiosarcoma 12.4
38 prostate angiosarcoma 12.4
39 aorta angiosarcoma 12.3
40 gallbladder angiosarcoma 12.3
41 mediastinum angiosarcoma 12.2
42 ovarian angiosarcoma 12.2
43 superior vena cava angiosarcoma 12.2
44 radiation induced angiosarcoma of the breast 12.2
45 central nervous system angiosarcoma 12.2
46 conventional angiosarcoma 12.1
47 pseudoangiomatous stromal hyperplasia 11.0
48 bone angioendothelial sarcoma 11.0
49 lymphedema 10.4
50 hemifacial spasm 10.4 FLT4 VEGFA

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 FLT1 KDR KRAS MUC1 VIM
2 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FLT1 KIT TEK

MGI Mouse Phenotypes related to Angiosarcoma:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 FLI1 FLT1 FLT4 KDR KIT KRAS
2 hematopoietic system MP:0005397 10.32 FLI1 FLT1 KDR KIT KRAS KRT8
3 homeostasis/metabolism MP:0005376 10.31 FLT1 FLT4 KDR KIT KRAS KRT8
4 cellular MP:0005384 10.3 FLI1 FLT1 KDR KIT KRAS MYC
5 immune system MP:0005387 10.29 FLI1 FLT1 FLT4 KDR KIT KRAS
6 embryo MP:0005380 10.28 FLI1 FLT1 FLT4 KDR KIT KRAS
7 growth/size/body region MP:0005378 10.26 FLI1 FLT1 FLT4 KDR KIT KRAS
8 mortality/aging MP:0010768 10.25 FLI1 FLT1 FLT4 KDR KIT KRAS
9 digestive/alimentary MP:0005381 10.2 FLT4 KIT KRAS KRT8 MYC PECAM1
10 muscle MP:0005369 10.18 FLI1 FLT1 FLT4 KDR KIT KRAS
11 liver/biliary system MP:0005370 10.16 FLI1 FLT4 KDR KIT KRAS KRT8
12 nervous system MP:0003631 10.11 FLI1 FLT1 KDR KIT KRAS MYC
13 normal MP:0002873 9.91 FLT1 FLT4 KDR KIT KRAS MYC
14 no phenotypic analysis MP:0003012 9.87 FLT4 KDR KIT KRAS MYC VEGFA
15 reproductive system MP:0005389 9.76 FLT1 FLT4 KIT KRAS KRT8 MYC
16 respiratory system MP:0005388 9.5 KDR KIT KRAS PECAM1 PROX1 VEGFA
17 vision/eye MP:0005391 9.23 FLT1 KDR KIT KRAS PROX1 TEK

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
6
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
9
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
10
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Histamine Approved, Investigational Phase 3 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Immunologic Factors Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 3,Phase 2
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
31 Antibodies Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Histamine Antagonists Phase 3
35 Gastrointestinal Agents Phase 3
36 Serotonin Agents Phase 3
37 Serotonin Antagonists Phase 3
38 Anti-Allergic Agents Phase 3
39 Antipruritics Phase 3
40 Dermatologic Agents Phase 3
41 Histamine H1 Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
46
Propranolol Approved, Investigational Phase 1, Phase 2 525-66-6 4946
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
12 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
13 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma Active, not recruiting NCT02979899 Phase 3 Votrient
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Unknown status NCT01303497 Phase 2 Paclitaxel;Bevacizumab
17 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) Unknown status NCT02732678 Phase 1, Phase 2 PROPRANOLOL
18 Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery Unknown status NCT00874874 Phase 2 sorafenib tosylate
19 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Completed NCT01623869 Phase 2
22 Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery Completed NCT00217607 Phase 2 paclitaxel
23 Bevacizumab in Treating Patients With Angiosarcoma Completed NCT00288015 Phase 2
24 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
25 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
26 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
30 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
31 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
32 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
33 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
35 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
36 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
37 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
38 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
39 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
40 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
41 Paclitaxel-Avelumab for Angiosarcoma Recruiting NCT03512834 Phase 2 Avelumab;Paclitaxel
42 Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma Recruiting NCT03921073 Phase 2 T-VEC
43 Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Recruiting NCT03331250 Phase 2 Eribulin
44 Evaluation of Votrient in Angiosarcoma Recruiting NCT02212015 Phase 2 Pazopanib + Paclitaxel
45 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting NCT01462630 Phase 2 pazopanib hydrochloride
46 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Recruiting NCT02048722 Phase 2 regorafenib
47 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
48 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
49 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
50 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

42
Breast, Liver, Bone, Heart, Lung, Spleen, Thyroid

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 3280)
# Title Authors Year
1
Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study. ( 30676608 )
2019
2
CT and MRI studies of hepatic angiosarcoma. ( 30686504 )
2019
3
A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. ( 30703514 )
2019
4
Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment. ( 30704938 )
2019
5
Clinical Outcomes and Prognostic Features of Angiosarcoma: Significance of Prior Radiation Therapy. ( 30718086 )
2019
6
ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. ( 30719217 )
2019
7
Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. ( 30723294 )
2019
8
Early appearance of post-radiation angiosarcoma of the breast. ( 30727036 )
2019
9
Marrow involvement by metastatic spindle cell angiosarcoma. ( 30733205 )
2019
10
Primary renal angiosarcoma with extensive hemorrhage: CT and MRI findings. ( 30735338 )
2019
11
Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy - A Systematic Review. ( 30738715 )
2019
12
Clinical and imaging manifestations of primary cardiac angiosarcoma. ( 30764784 )
2019
13
Regulation of PD-L1 expression by aPKCλ in cutaneous angiosarcoma. ( 30801864 )
2019
14
Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma. ( 30820717 )
2019
15
Corrigendum to 'Primary thyroid angiosarcoma: A systematic review' [Oral Oncol. 82 (2018) 48-52]. ( 30824286 )
2019
16
SIRT1 Expression Is Associated With Cell Proliferation in Angiosarcoma. ( 30842143 )
2019
17
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma. ( 30850173 )
2019
18
Primary pulmonary angiosarcoma: case reports and review of the literature. ( 30857394 )
2019
19
A case of aggressive recurrent intracranial subdural hematoma associated with angiosarcoma originating from the skull. ( 30862578 )
2019
20
Terminal Bleeding in Angiosarcoma. ( 30864873 )
2019
21
Anti-Amphiphysin-associated limbic encephalitis in a 72-year-old patient with aortic angiosarcoma. ( 30872337 )
2019
22
Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC). ( 30877870 )
2019
23
A case of recurrent angiosarcoma with isolated bone marrow metastasis presented as acute disseminated intravascular coagulation. ( 30887676 )
2019
24
Primary Renal Angiosarcoma Mimicking Renal Cell Carcinoma: A Case Report. ( 30891382 )
2019
25
A rare case of primary well-differentiated angiosarcoma of the right atrium. ( 30923549 )
2019
26
Angiosarcoma of the anal margin associated with complete rectal prolapse. ( 30928126 )
2019
27
FDG PET/CT Findings of Unsuspected Pulmonary Epithelioid Angiosarcoma Manifested as a Brain Metastasis. ( 30932976 )
2019
28
Primary Epithelioid Angiosarcoma of the Breast: A Rare and Challenging Biopsy Diagnosis. ( 30940796 )
2019
29
Aortic angiosarcoma masquerading as inflammatory aortitis. ( 30943140 )
2019
30
Primary cardiac angiosarcoma with right atrial wall rupture: A case report. ( 30946333 )
2019
31
Case of low-grade primary angiosarcoma of the breast with early recurrence. ( 30953382 )
2019
32
A Case of Radiation-Associated Angiosarcoma After Laryngeal Cancer. ( 30955372 )
2019
33
A 27-year-old female presented with diffuse alveolar haemorrhage due to breast angiosarcoma with lung metastasis. ( 30956793 )
2019
34
Anastomosing Hemangioma: Short Review of a Benign Mimicker of Angiosarcoma. ( 30958692 )
2019
35
Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy. ( 30977252 )
2019
36
Colonic Angiosarcoma: A Rare Gastrointestinal Malignancy. ( 30981006 )
2019
37
Hypopyon sign in dermatoscopy of cutaneous angiosarcoma. ( 30982952 )
2019
38
Angiosarcoma of the Liver: Clinicopathologic Features and Morphologic Patterns. ( 30986799 )
2019
39
Primary cardiac epithelioid angiosarcoma with frond-like features: a rare and ominous radiological mimicker of benign cardiac tumors. ( 31005792 )
2019
40
Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report. ( 31012199 )
2019
41
Primary Left Atrial Angiosarcoma Presenting as Acute Coronary Syndrome. ( 31013229 )
2019
42
Skull angiosarcoma associated with a calcified chronic subdural hematoma. ( 31014116 )
2019
43
Early Breast Angiosarcoma Development After Radiotherapy: A Cautionary Tale. ( 31021840 )
2019
44
The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: A case report. ( 31027090 )
2019
45
Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation. ( 31061188 )
2019
46
Radiation-associated angiosarcoma with histological features reminiscent of Kaposi's sarcoma successfully treated by radiotherapy with paclitaxel. ( 31087582 )
2019
47
Diethylnitrosamine (DENA) recapitulates formation of hepatic angiosarcoma in pigs. ( 31095587 )
2019
48
Epithelioid Angiosarcoma: An Unusual Cause of Gastrointestinal Bleeding. ( 29944034 )
2019
49
Radiation-induced angiosarcoma of the breast in a Li-Fraumeni patient. ( 30001797 )
2019
50
An unexpected diagnosis: angiosarcoma with bone marrow involvement mimicking a myeloproliferative neoplasm. ( 30203835 )
2019

Variations for Angiosarcoma

ClinVar genetic disease variations for Angiosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MED12 NM_005120.2(MED12): c.130G> A (p.Gly44Ser) single nucleotide variant other rs199469669 GRCh37 Chromosome X, 70339253: 70339253
2 MED12 NM_005120.2(MED12): c.130G> A (p.Gly44Ser) single nucleotide variant other rs199469669 GRCh38 Chromosome X, 71119403: 71119403
3 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh38 Chromosome 12, 25245328: 25245328
4 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
5 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
6 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh38 Chromosome 12, 25245328: 25245328

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 FLT1 FLT4 KDR KIT KRAS MUC1
2
Show member pathways
13.64 FLT1 FLT4 KDR KIT KRAS MYC
3
Show member pathways
13.46 FLT1 FLT4 KDR KIT KRAS MYC
4
Show member pathways
13.42 KDR KIT KRAS KRT8 TEK VEGFA
5
Show member pathways
13.26 KIT KRAS MUC1 MYC TEK VEGFA
6
Show member pathways
13.25 FLT1 FLT4 KDR KIT KRAS TEK
7
Show member pathways
13.23 FLT1 FLT4 KDR KIT KRAS TEK
8
Show member pathways
13.18 FLT1 FLT4 KDR KIT KRAS TEK
9
Show member pathways
12.99 FLT1 FLT4 KDR KIT KRAS
10
Show member pathways
12.98 FLT1 FLT4 KDR KIT KRAS
11
Show member pathways
12.92 FLT1 FLT4 KDR KIT TEK
12
Show member pathways
12.83 FLT1 FLT4 KDR KRAS VEGFA VWF
13 12.77 FLT4 KIT KRAS MYC VEGFA
14
Show member pathways
12.64 FLT1 FLT4 KDR KIT KRAS MYC
15
Show member pathways
12.62 FLT1 FLT4 KDR KIT KRAS TEK
16 12.53 FLT1 FLT4 KDR KIT KRAS MYC
17 12.46 KRAS MYC VEGFA VIM
18
Show member pathways
12.44 FLT1 FLT4 KDR KRAS
19
Show member pathways
12.38 FLT1 FLT4 KDR KRAS
20
Show member pathways
12.36 FLT1 FLT4 KDR KRAS VEGFA
21
Show member pathways
12.34 FLT1 FLT4 KDR VEGFA
22
Show member pathways
12.31 FLT1 FLT4 KDR KIT KRAS TEK
23 12.24 KDR KRAS MYC VEGFA
24
Show member pathways
12.2 FLT1 FLT4 KDR KIT KRAS MYC
25
Show member pathways
12.18 FLT1 KDR KRAS VEGFA
26
Show member pathways
12.12 FLT1 FLT4 KDR KRAS MYC TEK
27 12.06 FLT1 FLT4 KDR KIT TEK
28 12.02 KDR PECAM1 VEGFA
29
Show member pathways
12.02 FLT1 FLT4 KDR KRAS MYC
30 12 KDR MYC PROX1 VEGFA VIM
31 11.95 FLT1 FLT4 KDR KRAS MYC TEK
32
Show member pathways
11.93 FLT1 KDR VEGFA
33 11.93 MUC1 MYC VEGFA VIM
34 11.86 FLT1 TEK VEGFA
35
Show member pathways
11.82 KIT MYC VEGFA
36
Show member pathways
11.82 FLT1 FLT4 KDR VEGFA
37 11.8 FLT1 TEK VEGFA
38 11.69 KRAS MYC VEGFA
39
Show member pathways
11.69 FLT1 FLT4 KDR KIT KRAS
40 11.63 KIT KRAS MYC
41 11.49 KRAS MYC VEGFA
42 11.31 FLT1 KDR VEGFA
43 11.12 FLT1 FLT4 KDR PECAM1 PROX1 TEK
44 11.09 FLT1 KDR TEK VEGFA
45 11.07 FLT1 FLT4 KDR KRAS MYC VEGFA
46 11.06 FLT1 FLT4 KDR VEGFA
47 10.95 FLT1 FLT4 KDR KIT TEK VIM

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 FLT1 FLT4 KDR KIT MUC1 TEK
2 cytoplasm GO:0005737 9.77 FLT1 FLT4 KDR KIT KRAS KRT8
3 focal adhesion GO:0005925 9.56 FLT1 KRAS TEK VIM
4 membrane raft GO:0045121 9.46 KDR KRAS PECAM1 TEK
5 receptor complex GO:0043235 9.02 FLT1 FLT4 KDR KIT TEK

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 FLT1 FLT4 KDR KIT TEK
2 positive regulation of protein phosphorylation GO:0001934 9.95 FLT4 KDR KRAS TEK VEGFA
3 positive regulation of cell migration GO:0030335 9.93 FLT1 KDR KIT VEGFA
4 MAPK cascade GO:0000165 9.93 KIT KRAS MYC TEK
5 positive regulation of angiogenesis GO:0045766 9.91 FLT1 KDR TEK VEGFA
6 peptidyl-tyrosine phosphorylation GO:0018108 9.91 FLT1 FLT4 KDR KIT TEK
7 cytokine-mediated signaling pathway GO:0019221 9.91 KIT KRAS MUC1 MYC VEGFA VIM
8 protein autophosphorylation GO:0046777 9.89 FLT1 FLT4 KDR KIT TEK
9 cell differentiation GO:0030154 9.88 FLI1 FLT1 KDR VEGFA
10 negative regulation of apoptotic process GO:0043066 9.88 FLT4 KDR MYC TEK VEGFA
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.86 FLT1 KDR KIT TEK
12 platelet degranulation GO:0002576 9.85 PECAM1 VEGFA VWF
13 angiogenesis GO:0001525 9.85 FLT1 FLT4 KDR PECAM1 TEK VEGFA
14 positive regulation of MAP kinase activity GO:0043406 9.84 FLT1 KIT KRAS VEGFA
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.83 FLT1 FLT4 KDR VEGFA
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 KIT PECAM1 VEGFA
17 ovarian follicle development GO:0001541 9.79 KIT MYC VEGFA
18 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.77 FLT1 KIT TEK
19 sprouting angiogenesis GO:0002040 9.77 FLT4 TEK VEGFA
20 positive regulation of MAPK cascade GO:0043410 9.76 FLT1 FLT4 KDR KIT
21 positive regulation of cell proliferation GO:0008284 9.76 FLT1 FLT4 KDR KIT KRAS MYC
22 positive regulation of focal adhesion assembly GO:0051894 9.75 KDR TEK VEGFA
23 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 FLT1 FLT4 KDR KIT TEK
24 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.71 FLT1 FLT4 KDR VEGFA
25 cell migration involved in sprouting angiogenesis GO:0002042 9.68 KDR VEGFA
26 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 FLT1 VEGFA
27 embryonic hemopoiesis GO:0035162 9.67 KDR KIT
28 megakaryocyte development GO:0035855 9.67 FLI1 KIT
29 positive regulation of phospholipase C activity GO:0010863 9.66 FLT1 KIT
30 lymph vessel development GO:0001945 9.65 FLT4 PROX1
31 lymphangiogenesis GO:0001946 9.65 FLT4 PROX1
32 positive regulation of positive chemotaxis GO:0050927 9.65 KDR VEGFA
33 positive regulation of endothelial cell proliferation GO:0001938 9.65 FLT4 KDR PROX1 TEK VEGFA
34 positive regulation of protein kinase C signaling GO:0090037 9.64 FLT4 VEGFA
35 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
36 vascular endothelial growth factor signaling pathway GO:0038084 9.26 FLT1 FLT4 KDR VEGFA
37 positive regulation of endothelial cell migration GO:0010595 9.02 FLT4 KDR PROX1 TEK VEGFA
38 phosphorylation GO:0016310 10.06 FLT1 FLT4 KDR KIT TEK
39 protein phosphorylation GO:0006468 10.06 FLT1 FLT4 KDR KIT TEK
40 positive regulation of gene expression GO:0010628 10.02 KIT KRAS MYC VEGFA VIM

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 FLT1 FLT4 KDR KIT TEK
2 protein kinase activity GO:0004672 9.77 FLT1 FLT4 KDR KIT TEK
3 protein tyrosine kinase activity GO:0004713 9.65 FLT1 FLT4 KDR KIT TEK
4 growth factor binding GO:0019838 9.46 FLT1 FLT4 KDR TEK
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.13 FLT1 FLT4 KDR
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT TEK
7 protein binding GO:0005515 10.2 FLI1 FLT1 FLT4 KDR KIT KRAS

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....